$RMHI
Retrieve Medical Holdings, Inc.

2020 Q3 Form 10-K Financial Statement

#000119983522000830 Filed on December 19, 2022

View on sec.gov

Income Statement

Concept 2020 Q3 2020 2019 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.540K
YoY Change -2.46%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $5.535K
YoY Change -2.62%
Operating Profit -$5.535K
YoY Change -2.62%
Interest Expense $9.476K
YoY Change 14.05%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$15.01K
YoY Change 7.29%
Income Tax
% Of Pretax Income
Net Earnings -$15.01K
YoY Change 7.28%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$191.50
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $410.00
YoY Change -22.64%
Cash & Equivalents $0.00 $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $408.00 $410.00 $527.00
YoY Change -22.58% -22.64% -76.78%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $408.00 $410.00 $527.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $408.00 $410.00 $527.00
YoY Change -22.58% -22.64% -76.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $162.5K $162.5K $157.1K
YoY Change 3.45% 3.44% 2.57%
Accrued Expenses $24.97K $24.97K $15.50K
YoY Change 61.16% 61.1% 115.63%
Deferred Revenue
YoY Change
Short-Term Debt $20.00K
YoY Change 0.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $250.5K $207.5K $235.6K
YoY Change 6.32% 7.73% 5.48%
LONG-TERM LIABILITIES
Long-Term Debt $43.00K
YoY Change 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $43.00K
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $250.5K $207.5K $235.6K
Total Long-Term Liabilities $43.00K
Total Liabilities $250.5K $250.5K $235.6K
YoY Change 6.32% 6.32% 5.48%
SHAREHOLDERS EQUITY
Retained Earnings -$5.113M -$5.098M
YoY Change 0.29% 0.28%
Common Stock $7.836K $7.836K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$250.1K -$250.1K -$235.1K
YoY Change
Total Liabilities & Shareholders Equity $408.00 $410.00 $527.00
YoY Change -22.58% -22.64% -76.78%

Cashflow Statement

Concept 2020 Q3 2020 2019 Q3
OPERATING ACTIVITIES
Net Income -$15.01K
YoY Change 7.28%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$119.00
YoY Change -93.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -$119.00
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -$119.00
YoY Change -93.17%
FREE CASH FLOW
Cash From Operating Activities -$119.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2021Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2020Q3 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001452804
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
usd
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2020 pkph Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
usd
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
005-87668
CY2021 dei Entity Registrant Name
EntityRegistrantName
PEAK PHARMACEUTICALS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1973257
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
14201 N. Hayden Road
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A-1
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Scottsdale
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85260
CY2021 dei City Area Code
CityAreaCode
(480)
CY2021 dei Local Phone Number
LocalPhoneNumber
659-6404
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Entity Shell Company
EntityShellCompany
true
CY2021Q1 dei Entity Public Float
EntityPublicFloat
8949300 usd
CY2020Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
20000 usd
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
283000 usd
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
43000 usd
CY2021Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
35000 usd
CY2021Q3 us-gaap Liabilities
Liabilities
587337 usd
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78363567 shares
CY2021 dei Auditor Name
AuditorName
Friedman LLP
CY2021 dei Auditor Location
AuditorLocation
Marlton, New Jersey
CY2021Q3 us-gaap Cash
Cash
261152 usd
CY2020Q3 us-gaap Cash
Cash
408 usd
CY2021Q3 us-gaap Assets
Assets
261152 usd
CY2020Q3 us-gaap Assets
Assets
408 usd
CY2021Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
133986 usd
CY2020Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
88020 usd
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
214136 usd
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
162532 usd
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
35201 usd
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
24972 usd
CY2021Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
20000 usd
CY2020Q3 us-gaap Liabilities
Liabilities
250504 usd
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78363567 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78363567 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78363567 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78363567 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
7836 usd
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
7836 usd
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4855566 usd
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4855566 usd
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5189587 usd
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5113498 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-326185 usd
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-250096 usd
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
261152 usd
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
408 usd
CY2021 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
40608 usd
CY2020 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
783 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
68721 usd
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5535 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
68721 usd
CY2020 us-gaap Operating Expenses
OperatingExpenses
5535 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-68721 usd
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-5535 usd
CY2021 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
24 usd
CY2020 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0 usd
CY2021 us-gaap Interest Expense
InterestExpense
10397 usd
CY2020 us-gaap Interest Expense
InterestExpense
9476 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3029 usd
CY2021 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-7368 usd
CY2020 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-9476 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-76089 usd
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15011 usd
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78363567 shares
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
78363567 shares
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-235085 usd
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15011 usd
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-250096 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-76089 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-326185 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-76089 usd
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15011 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
3029 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8667 usd
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4632 usd
CY2021 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
45966 usd
CY2020 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
783 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
10229 usd
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
9477 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14256 usd
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-119 usd
CY2021 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
240000 usd
CY2021 pkph Proceeds From Notes Payable Related Party
ProceedsFromNotesPayableRelatedParty
35000 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
275000 usd
CY2021 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
260744 usd
CY2020 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
-119 usd
CY2020Q3 us-gaap Cash
Cash
408 usd
CY2019Q3 us-gaap Cash
Cash
527 usd
CY2021Q3 us-gaap Cash
Cash
261152 usd
CY2020Q3 us-gaap Cash
Cash
408 usd
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3058935 shares
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3291000 shares
CY2021Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
133986 usd
CY2020Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
88020 usd
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_zPtqGKJYNxrh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86E_ztkXt1mqAX69">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates made in connection with the accompanying consolidated financial statements include the valuation allowances against net deferred tax assets and accounting for convertible debt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
311210 shares
CY2021 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
40608 usd
CY2020 us-gaap Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party
RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
783 usd
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3291000 shares
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039 pure
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5189587 usd
CY2021Q3 pkph Working Captial Deficiency
WorkingCaptialDeficiency
-326185 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14256 usd
CY2021Q3 us-gaap Cash
Cash
261152 usd
CY2021 pkph Disclosure Options Details Abstract
DisclosureOptionsDetailsAbstract
<table cellpadding="0" cellspacing="0" id="xdx_88A_ecustom--DisclosureOptionsDetailsAbstract_zie1CnGy8WGf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - OPTIONS (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Number<br/> of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Exercise Price per<br/> Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Average<br/> Remaining<br/> Term in<br/> Years</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 51%; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">Outstanding September 30, 2021 and 2020</td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zIlJ206FluHg"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20200930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zO53HG0If8Aj">2,916,000</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zVvp7AfrHXh3"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20200930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zE5RC2Eu29yg">0.0067</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxH_c20201001__20210930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zp7d13hS2xx2" title="::XDX::P2Y5M12D"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxH_c20191001__20200930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zSVBmVLLCyA7" title="::XDX::P2Y5M12D">2.45</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zFIMVBVUOI23"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20200930__us-gaap--AwardTypeAxis__custom--EmployeeMember_z5L4VWGkfkie">2,916,000</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zfKsurayZB0c"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20200930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zwNJCrP7PTE8">0.0067</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxH_c20191001__20200930__us-gaap--AwardTypeAxis__custom--EmployeeMember_zGbcZn3M44Z9" title="::XDX::P2Y5M12D"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxH_c20201001__20210930__us-gaap--AwardTypeAxis__custom--EmployeeMember_ztAmOqhzNlvj" title="::XDX::P2Y5M12D">2.45</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2021 pkph Disclosure Options Details2 Abstract
DisclosureOptionsDetails2Abstract
<table cellpadding="0" cellspacing="0" id="xdx_885_ecustom--DisclosureOptionsDetails2Abstract_z5dfJ7rbS334" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%" summary="xdx: Disclosure - OPTIONS (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Number<br/> of Options</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Exercise Price per<br/> Share</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; text-align: center">Average<br/> Remaining<br/> Term<br/> in Years</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; text-align: center"> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td><td> </td> <td colspan="2" style="white-space: nowrap; text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 51%; padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">Outstanding September 30, 2021 and 2020</td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_z4rukACbEZle"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20200930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_z77G9et5n5U5">375,000</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20210930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zBmm8XyiymR2"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20200930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_z5WZccslbHv">0.0067</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td><td style="width: 3%; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; width: 8%; text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxH_c20201001__20210930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zh9D5O9ayMQb" title="::XDX::P2Y14D"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dxH_c20191001__20200930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zu7EwFdQPHub" title="::XDX::P2Y14D">2.04</span></span></td><td style="white-space: nowrap; width: 1%; padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-indent: 0pt; padding-left: 0pt">Exercisable</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20210930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_z8uM37ULhgH7"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20200930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_z5jTktVFUEDe">375,000</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20210930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zVvuA0UEqBTi"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20200930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zyd8M1uEKRUb">0.0067</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxH_c20201001__20210930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zfO31jSV7OIl" title="::XDX::P2Y14D"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dxH_c20191001__20200930__us-gaap--AwardTypeAxis__custom--NonEmployeeMember_zFIoqK4vlSPd" title="::XDX::P2Y14D">2.04</span></span></td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-16000 usd
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3200 usd
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-3000 usd
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-600 usd
CY2021 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-19000 usd
CY2020 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-3800 usd
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
19000 usd
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
3800 usd
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.249 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.249 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2021Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
302000 usd
CY2020Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
283000 usd
CY2021Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
302000 usd
CY2020Q3 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
283000 usd
CY2021Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
302000 usd
CY2020Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
283000 usd
CY2021Q3 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
19000 usd
CY2020Q3 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
4000 usd
CY2021Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1215000 usd
CY2020Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
1139000 usd

Files In Submission

Name View Source Status
0001199835-22-000830-index-headers.html Edgar Link pending
0001199835-22-000830-index.html Edgar Link pending
0001199835-22-000830.txt Edgar Link pending
0001199835-22-000830-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pkph-20210930.xsd Edgar Link pending
pkph093021-10k.htm Edgar Link pending
pkph093021-ex10_10.htm Edgar Link pending
pkph093021-ex10_11.htm Edgar Link pending
pkph093021-ex10_12.htm Edgar Link pending
pkph093021-ex10_13.htm Edgar Link pending
pkph093021-ex10_14.htm Edgar Link pending
pkph093021-ex10_15.htm Edgar Link pending
pkph093021-ex10_16.htm Edgar Link pending
pkph093021-ex10_17.htm Edgar Link pending
pkph093021-ex10_18.htm Edgar Link pending
pkph093021-ex10_19.htm Edgar Link pending
pkph093021-ex10_20.htm Edgar Link pending
pkph093021-ex31_1.htm Edgar Link pending
pkph093021-ex31_2.htm Edgar Link pending
pkph-20210930_def.xml Edgar Link unprocessable
pkph-20210930_lab.xml Edgar Link unprocessable
pkph-20210930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pkph-20210930_cal.xml Edgar Link unprocessable
pkph093021-10k_htm.xml Edgar Link completed
pkph093021-ex32_1.htm Edgar Link pending
pkph093021-ex32_2.htm Edgar Link pending
pp001_v1.jpg Edgar Link pending
pp002_v1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending